Targeted cancer drug trial cut short after enrolling only 14 patients
NCT ID NCT04617054
First seen Jan 21, 2026 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tested a daily pill called AB-106 in people whose solid tumors had spread and carried a specific gene change (NTRK fusion). The goal was to see if the drug could shrink tumors. The trial was stopped early and included only 14 participants who had already tried other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chinese PLA General Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.